GlassScriptPhysician profile
Brianne T Nicoletti
NPI 1225320625
$1,213.91
in general payments reported to CMS, 2019-2025
13 companies · $944 in 2025
The $944 reported for 2025 was more than what 78% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.17 · 2020: $12.59 · 2024: $216 · 2025: $944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,160.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $437.51 | 2019-2025 | Dovato, Rukobia, Apretude |
| Insmed, INC. | $267.99 | 2024-2025 | Arikayce, Brinsupri |
| Aimmune Therapeutics, INC. | $96.23 | 2025 | Vowst |
| Merck Sharp & Dohme LLC | $77.23 | 2020-2025 | Pifeltro, Capvaxive |
| Shionogi INC | $66.79 | 2025 | Fetroja |
| Paratek Pharmaceuticals, INC. | $47.39 | 2025 | Nuzyra |
| Gilead Sciences, INC. | $41.97 | 2025 | Biktarvy |
| Takeda Pharmaceuticals U.S.A., INC. | $41.07 | 2024 | Hyqvia |
| Astellas Pharma US INC | $40.64 | 2025 | Cresemba |
| Melinta Therapeutics, LLC | $34.23 | 2025 | Rezzayo, Kimyrsa, Orbactiv |
| Octapharma USA, INC. | $21.95 | 2025 | Octagam Immune Globulin (Human) |
| Ferring Pharmaceuticals INC. | $21.24 | 2025 | Rebyota |
| La Jolla Pharmaceutical Company | $19.67 | 2025 | Zevtera |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brianne Nicoletti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.